Overall market sentiment has been high on Aethlon Medical, Inc. (AEMD) stock lately. AEMD receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With AEMD Stock Today?
Aethlon Medical, Inc. (AEMD) stock is down -12.74% while the S&P 500 has gained 0.62% as of 11:27 AM on Friday, May 29. AEMD has fallen -$0.20 from the previous closing price of $1.57 on volume of 316,643 shares. Over the past year the S&P 500 is up 9.77% while AEMD has fallen -75.67%. AEMD lost -$4.51 per share in the over the last 12 months.
To see the top 5 stocks in the Medical Devices industry click here.
More About Aethlon Medical, Inc.
Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from government contracts.
